A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Last updated:
2026-07-18
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A)

Intervention/treatment:
LEPODISIRAN (LY3819469)
Medical condition:
CARDIOVASCULAR DISEASE
Protocol code:
J3L-MC-EZEF
Control number:
282813
Status:
Active, not recruiting
Approved:
February 09, 2024
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT06292013
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Sponsor
ELI LILLY CANADA INC

Locations

ALPHA Recherche Clinique
Québec, G3K 2P8
ARC Biosystems
Vancouver, V6Z 2H2
Cardio Health Clinical Trial - Brampton
Brampton, L6Y 6H4
Cardio Health Clinical Trial - London
London, N6H 5L4
Cardio Health Clinical Trial - St. Thomas
St. Thomas, N5R 2R4
Care Access - Cape Breton
Sydney, B1M 0A1
Centre de Medecine Metabolique de Lanaudiere (CMML)
Terrebonne, J6X 4P7
Clinique des Maladies Lipidiques de Québec
Québec, G1V 4W2
Corcare
Toronto, M1B 5N1
Diabetes Heart Research Centre
Toronto, M6G 1M2
Diex Recherche Inc. Division Joliette
Joliette, J6E 6A9
Diex Recherche Inc. Division Trois-Rivieres
Trois-Rivières, G9A 4P3
Discovery Clinical Services
Victoria, V8T 5G4
Ecogene-21
Chicoutimi, G7H 7K9
Fraser Clinical Trials Inc
New Westminster, V3L 3W4
G A Research Associates
Moncton, E1G 1A7
Medical Arts Health Research Group
Penticton, V2A 5L5
Milestone Research Inc.
London, N5W 6A2
North York Diagnostic and Cardiac Centre
North York, M6B 3H7
Oakville Cardiovascular Research LP
Oakville, L6K 3W7
Premier Clinical Trial Network
Hamilton, L8L5G4
SMH Cardiology Clinical Trials
Surrey, V3V 0C6
The Medical Arts Health Research Group
North Vancouver, V7P 2T4
Unité de Recherche Clinique du CISSS des Laurentides
Saint-Jérôme, J7Z 2V4
Viacar Recherche Clinique
Longueuil, J4H 4B9
Victoria Heart Institute Foundation
Victoria, V8R 1B2
Winnipeg Clinic
Winnipeg, R3C 0N2
Did you find what you were looking for?